Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Investment Income: 2017-2024

Historic Non Operating Investment Income for Ligand Pharmaceuticals (LGND) over the last 8 years, with Dec 2024 value amounting to $75.0 million.

  • Ligand Pharmaceuticals' Non Operating Investment Income rose 223.97% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.5 million, marking a year-over-year decrease of 123.95%. This contributed to the annual value of $75.0 million for FY2024, which is 61.81% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Non Operating Investment Income stood at $75.0 million for FY2024, which was up 61.81% from $46.4 million recorded in FY2023.
  • Ligand Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $75.0 million during FY2024, with a 5-year trough of -$16.9 million in FY2020.
  • For the 3-year period, Ligand Pharmaceuticals' Non Operating Investment Income averaged around $50.0 million, with its median value being $46.4 million (2023).
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 1,714.20% in 2020, then soared by 642.28% in 2022.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Non Operating Investment Income stood at -$16.9 million in 2020, then soared by 68.92% to -$5.3 million in 2021, then surged by 642.28% to $28.5 million in 2022, then surged by 62.46% to $46.4 million in 2023, then soared by 61.81% to $75.0 million in 2024.